Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature

Sonpavde, Guru, Attard, Gerhardt, Bellmunt, Joaquim, Mason, Malcolm David ORCID: https://orcid.org/0000-0003-1505-2869, Malavaud, Bernard, Tombal, Bertrand and Sternberg, Cora N. 2011. The role of abiraterone acetate in the management of prostate cancer: a critical analysis of the literature. European Urology 60 (2) , pp. 270-278. 10.1016/j.eururo.2011.04.032

Full text not available from this repository.

Abstract

Context The development of agents targeting androgen signalling holds promise for men with castration-resistant prostate cancer (CRPC). Objective The emerging role of abiraterone acetate (AA), a novel, orally administered androgen synthesis inhibitor, is critically analysed. Evidence acquisition Data were acquired from critically important original research published in peer-reviewed literature or presented at conferences conducted by the American Society of Clinical Oncology and the European Society of Medical Oncology. Evidence synthesis The major findings are addressed in an evidence-based, objective, and balanced fashion. Conclusions AA specifically inhibits CYP17 and substantially reduces serum androgen levels without inducing significant adrenal insufficiency. A phase 3 trial reported a significant extension of survival in metastatic CRPC with AA plus prednisone compared to prednisone alone following docetaxel. The primary toxicity of mineralocorticoid excess is manageable. The addition of low-dose corticosteroids to AA may be necessary for controlling symptoms of mineralocorticoid excess.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Uncontrolled Keywords: abiraterone acetate (AA), castration resistant prostate cancer (CRPC), secondary hormonal therapy, CYP17, 17 α-Hydroxylase, 17,20-Lyase
Publisher: Elsevier
ISSN: 0302-2838
Last Modified: 19 Oct 2022 10:39
URI: https://orca.cardiff.ac.uk/id/eprint/25085

Citation Data

Cited 42 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item